IRIS
COLUCCI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.673
AS - Asia 3.442
EU - Europa 2.705
SA - Sud America 832
AF - Africa 172
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 6
Totale 16.836
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.570
SG - Singapore 1.477
CN - Cina 875
BR - Brasile 685
DE - Germania 466
HK - Hong Kong 465
SE - Svezia 454
RU - Federazione Russa 363
IT - Italia 299
FR - Francia 273
UA - Ucraina 259
FI - Finlandia 230
VN - Vietnam 165
GB - Regno Unito 162
IN - India 113
CI - Costa d'Avorio 63
BD - Bangladesh 62
AR - Argentina 51
IE - Irlanda 43
TR - Turchia 39
ZA - Sudafrica 38
CA - Canada 36
MX - Messico 35
IQ - Iraq 34
ID - Indonesia 27
NL - Olanda 27
PL - Polonia 27
EC - Ecuador 26
PK - Pakistan 26
PH - Filippine 25
BE - Belgio 24
SA - Arabia Saudita 24
JP - Giappone 22
CO - Colombia 21
VE - Venezuela 18
MA - Marocco 17
MY - Malesia 13
ES - Italia 12
PY - Paraguay 12
UZ - Uzbekistan 12
AT - Austria 11
EG - Egitto 11
TN - Tunisia 11
JO - Giordania 10
LT - Lituania 10
CL - Cile 9
DK - Danimarca 8
AE - Emirati Arabi Uniti 7
DO - Repubblica Dominicana 7
CZ - Repubblica Ceca 6
ET - Etiopia 6
IL - Israele 6
KR - Corea 6
AU - Australia 5
GR - Grecia 5
JM - Giamaica 5
SM - San Marino 5
UY - Uruguay 5
AL - Albania 4
AO - Angola 4
CR - Costa Rica 4
IR - Iran 4
KE - Kenya 4
KZ - Kazakistan 4
NG - Nigeria 4
AZ - Azerbaigian 3
EU - Europa 3
HN - Honduras 3
KW - Kuwait 3
LB - Libano 3
PE - Perù 3
RS - Serbia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
GD - Grenada 2
GT - Guatemala 2
KG - Kirghizistan 2
MD - Moldavia 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
BG - Bulgaria 1
BJ - Benin 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CM - Camerun 1
DJ - Gibuti 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
HU - Ungheria 1
Totale 16.819
Salva come PNG Salva come JPEG
Città #
Fairfield 1.157
Woodbridge 1.028
Ashburn 869
Singapore 781
Houston 698
Chandler 666
Jacksonville 607
Seattle 504
Hong Kong 461
Cambridge 412
Ann Arbor 397
Wilmington 386
Nyköping 380
San Jose 364
Beijing 249
Roxbury 161
Lawrence 159
Nanjing 158
Lauterbourg 143
Des Moines 97
New York 97
Dallas 93
Bari 92
Boardman 88
Los Angeles 78
Helsinki 73
Abidjan 63
São Paulo 63
Ho Chi Minh City 62
Princeton 62
San Diego 61
Brooklyn 55
Inglewood 52
Strasbourg 48
Santa Clara 46
Hebei 42
Nanchang 41
Shenyang 40
Dublin 39
Grafing 37
London 36
Buffalo 31
Hanoi 30
Frankfurt am Main 27
Tianjin 25
Brussels 24
Atlanta 23
Chicago 23
Orem 23
Jiaxing 21
Moscow 21
Belo Horizonte 20
Changsha 20
Dearborn 20
Johannesburg 20
Warsaw 20
Pune 19
Boston 18
Paris 18
Tokyo 18
Falkenstein 16
Mexico City 16
Munich 16
Rio de Janeiro 16
Baghdad 15
Council Bluffs 14
Dhaka 13
Guangzhou 13
Milan 13
Poplar 13
Denver 11
Jakarta 11
Manchester 11
Montreal 11
Mumbai 11
Quito 11
San Francisco 11
Amsterdam 10
Auburn Hills 10
Brasília 10
Campinas 10
Curitiba 10
Redwood City 10
Tashkent 10
Toronto 10
Amman 9
Kunming 9
Medellín 9
Nuremberg 9
Rome 9
San Mateo 9
Stockholm 9
Augusta 8
Cape Town 8
Caracas 8
Casablanca 8
Caxias do Sul 8
Chennai 8
Genoa 8
Jeddah 8
Totale 11.795
Salva come PNG Salva come JPEG
Nome #
Coagulopathy of Acute Sepsis 217
Platelet drop and fibrinolytic shutdown in patients with sepsis 200
Fisiologia dell'Emostasi 189
Factor IX-Padua enhances the fibrinolytic resistance of plasma clots 185
Histones differentially modulate the anticoagulant and profibrinolytic activities of heparin, heparin derivatives and dabigatran. 185
FVIII/VWF complex displays a greater pro-hemostatic activity than FVIII preparations devoid of VWF. Study in plasma and cell-based models 170
Coagulation activation is associated with nicotinamide adenine dinucleotide phosphate oxidase-dependent reactive oxygen species generation in hemodialysis patients. 169
Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation 160
A modified prothrombin time to measure the anticoagulant activity of dabigatran 159
A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression 159
Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles 157
Influence of cell-associated tissue factor concentration on the anticoagulant activity of dabigatran. A possible explanation for the reduced incidence of intracranial bleeding 155
Antithrombotic activity of 12 table grape varieties. Relationship with polyphenolic profile 154
Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection 153
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors 151
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation 148
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells 145
Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism 141
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor 141
Gene expression signature induced by grape intake in healthy subjects reveals wide-spread beneficial effects on peripheral blood mononuclear cells 141
Cultured human endothelial cells generate tissue factor in response to endotoxin 140
Effect of ochratoxin A on prothrombotic and proinflammatory activities of stimulated blood mononuclear cells 140
Blood and tissue fibrinolytic profile in patients with colorectal cancer 139
Platelets and fibrinolysis 139
Tissue factor in health and disease 138
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis 138
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway 136
Hyperprothrombinemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis 134
CHANGES IN THE COAGULATION-FIBRINOLYSIS BALANCE OF ENDOTHELIAL-CELLS AND MONONUCLEAR PHAGOCYTES - ROLE IN DISSEMINATED INTRAVASCULAR COAGULATION ASSOCIATED WITH INFECTIOUS-DISEASES 134
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis. Study in healthy subjects and correlation with blood fibrinolytic parameters 132
Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells 132
Sepsis, thrombosis and organ dysfunction 130
Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms. 130
A hitherto undescribed defect of platelet coagulant activity in polycythaemia vera and essential thrombocythaemia. 130
Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis 128
Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots 128
Reduced generation of procoagulant activity by endotoxin-stimulated mononuclear cells from patients with chronic myeloid leukaemia. 127
Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. 127
Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors 127
Low D-dimer levels in sepsis: Good or bad? 127
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation 126
Anomalie cellulari e plasmatiche della coagulazione e della fibrinolisi dei linfomi ed effetto della terapia 124
Cancer cell procoagulant activity: evaluation by an amidolytic assay. 124
A ROLE FOR PLATELETS AND THROMBIN IN THE JUVENILE STROKE OF 2 SIBLINGS WITH DEFECTIVE THROMBIN-ADSORBING CAPACITY OF FIBRIN(OGEN) 123
Cancer cell procoagulant: a novel vitamin K-dependent activity. 121
Cellular coagulation-fibrinolysis balance and atherosclerosis 120
Role of leucocyte procoagulant activity in endotoxin-induced DIC: evidence from comparative studies in rats and rabbits. 120
Extracellular histones promote fibrinolysis by single-chain urokinase-type plasminogen activator in a factor seven activating protease-dependent way 120
TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival 119
Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats. 117
Effect of Ochratoxin A on prothrombotic and proinflammatory activities of stimulated blood mononuclear cells 116
ENHANCED ENDOTHELIAL TISSUE FACTOR BUT NORMAL THROMBOMODULIN IN ENDOTOXIN-TREATED RABBITS. 116
Cellular and plasmatic anomalies of the coagulation system and fibrinolysis in children with lymphomas and influence of cytostatic treatment 115
Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential 114
Alterazioni dell'equilibrio coagulativo-fibrinolitico dei monociti e della capacità fibrinolitica plasmatica dei linfomi 114
Fibrin down-regulates LPS- and PMA- induced tissue factor expression by blood mononuclear cells 114
Monocytes, but not endothelial cells, downregulate the anticoagulant activity of activated protein C 113
NOVEL GLUCOSE-CONJUGATED HIGHLY POTENT DUAL THROMBIN AND FACTOR Xa INHIBITORS AS POTENTIAL ANTITHROMBOTICS 113
In vitro inhibition of monocyte tissue factor and PAI-2 production by Ochratoxin A 112
Unbalanced coagulation-fibrinolysis potential during L-Asparaginase therapy in children with acute lymphoblastic leukaemia 112
Evidence that fibrynolitic changes in paediatric obesity translate in a hypofibrinolytic state. Relative contribution of TAFI and PAI-1 112
Treatment with cyclosporin A does not affect macrophage procoagulant activity and plasminogen activator inhibitor in mice 112
FAILURE OF WARFARIN TO AFFECT THE TISSUE FACTOR ACTIVITY AND THE METASTATIC POTENTIAL OF MURINE FIBRO-SARCOMA CELLS. 111
Stroke in two young siblings with congenital dysfibrinogenemia. 111
Ochratoxin A inhibits the production of tissue factor and plasminogen activator inhibitor-2 by human blood mononuclear cells: Another potential mechanism of immune-suppression 111
Complement-dependent and complement-independent interactions of bacterial lipopolysaccharides and mucopeptides with rabbit and human platelets. 109
Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. 109
Procoagulant activity of sarcoma sublines with different metastatic potential 108
Does inhibiting Sur1 complement rtPA in cerebral ischemia? 108
URINARY PROCOAGULANT AND FIBRINOLYTIC-ACTIVITY IN HUMAN GLOMERULONEPHRITIS - RELATIONSHIP WITH RENAL-FUNCTION 108
Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma 106
Estressione del tisuue factor e del vasular endothelial growth factor nel carcinoma del colon retto 106
Reduction of the plasma levels of tissue plasminogen activator after infusion of a lipid emulsion in humans 106
Alterazioni dell'equilibrio coagulativo-fibrinolitico dei monociti e della capacità fibrinolitica plasmatica nei linfomi 106
Expression of tissue factor and vascular endothelial growth factor in colorectal carcinoma 106
The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood 106
Helicobacter pylori neutrophil activating protein stimulates tissue factor and plasminogen inhibitor-2 production by human blood mononuclear cells 105
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. 104
Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies 104
Early increase of a new platelet coagulant activity in rats fed a thrombogenic diet. 103
REDUCED FIBRINOLYTIC-ACTIVITY IN GLOMERULI ISOLATED FROM RABBITS INFUSED WITH TUMOR-NECROSIS-FACTOR. 102
Increased macrophage procoagulant activity but normal endothelial thrombomodulin in rabbits fed an atherogenic diet 101
The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation. 101
Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. 100
Diversi fattori contribuiscono alla ipofibrinolisi nei bambini obesi 100
Procoagulant properties of bare and highly-PEGylated vinyl-modified silica nanoparticles 99
Skin extracts from 2 italian table grapes (italia and palieri) inhibit tissue factor expression by human blood mononuclear cells 98
An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia 97
NOVEL GLUCOSE-CONJUGATED HIGHLY POTENT DUAL THROMBIN AND FACTOR Xa INHIBITORS AS POTENTIAL ANTITHROMBOTICS 96
Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis 96
Retinoids inhibit the respiratory burst and degranulation of stimulated human polymorphonuclear leukocytes 96
HEMOSTATIC VARIABLES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - EFFECT OF REGULAR PLASMA-CHOLESTEROL REMOVAL BY LOW-DENSITY-LIPOPROTEIN APHERESIS 96
Evidence that cells from experimental tumours can activate coagulation factor X. British journal of cancer. 95
Emostasi cellulare 95
Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis 95
EXPERIMENTAL ENDOTOXEMIA AS A MODEL OF IMPAIRED FIBRINOLYSIS 94
Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses 94
Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370 93
Thrombin Activatable Fibrinolysis Inhibitor: at the nexus of fibrinolysis and inflammation 92
TISSUE FACTOR-EXPRESSING MONOCYTES INHIBIT FIBRINOLYSIS THROUGH A TAFI-MEDIATED MECHANISM, AND MAKE CLOTS RESISTANT TO HEPARINS 91
Totale 12.370
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.431
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.431
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021333 0 0 0 0 0 0 0 0 0 201 81 51
2021/20221.168 57 200 11 40 60 50 63 53 80 62 199 293
2022/20231.795 263 191 134 163 211 233 23 169 326 13 35 34
2023/2024463 59 102 15 35 29 102 15 21 5 10 18 52
2024/20252.482 78 32 213 100 46 181 162 244 93 103 369 861
2025/20264.027 701 221 300 586 554 209 555 133 376 392 0 0
Totale 16.949